報價延遲最少15分鐘:2025/06/06 01:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.69 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.75/-2.27
|
|
企業價值
599.84M
|
| 資產負債 |
|
每股賬面淨值
2.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/06 01:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD). |